Syremis

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company's neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA antagonism. Its lead program, ST-905, is a dual M1/M4 agonist in Phase 1 development for schizophrenia; a second program, ST-901 (a novel NMDA antagonist), is in IND-enabling studies for major depressive disorder and bipolar depression. Both compounds were initially discovered at Clexio Biosciences and spun out to Syremis, which launched in December 2025 with a $165M Series A co-led by Dexcel Pharma and Third Rock Ventures.